Glaucoma Physician

Glaucoma Physician offers up-to-date insights on the rapidly changing field of glaucoma. Published quarterly, this resource shares the latest developments in advanced glaucoma treatment, featuring case studies, surgical methods, research findings, and discussions on how to manage patients with glaucoma effectively.

English

Magazine, Online/Digital

Outlet metrics

Domain Authority

Ranking

Global

#7154400

United States

#2200917

Articles

Optimizing Drop Size in Ophthalmic Applications

Nov 1, 2024 | glaucomaphysician.net | Constance Okeke

In ophthalmology, the administration of topical medications is a cornerstone for glaucoma management. However, commercially available drop sizes (30+ µL) exceed the eye’s capacity to retain the medication (7-10 µL), leading to excessive dosing, overflow, periorbital irritation, and drainage by the nasolacrimal ducts causing systemic absorption. The increased risk of systemic adverse effects (AEs), particularly with drug classes like beta-blockers, has additional implications for patient safety.
Practical Tips for Using iStent Infinite

Oct 31, 2024 | glaucomaphysician.net | Sahar Bedrood

Over the last decade, there has been a renaissance in glaucoma surgical treatment options when it comes to angle surgery as well as devices that can help encourage outflow through the trabecular meshwork.
Premium IOLs for POAG Patients

Oct 31, 2024 | glaucomaphysician.net | Zarmeena Vendal

Traditionally, the surgical space for cataract surgery has been very limited for primary open-angle glaucoma (POAG) patients. Fortunately, today we are on the forefront of innovation when it comes to finding a solution for these patients, because there are multiple lens implant choices that can help us push limits and provide satisfying visual outcomes.
From the Editor: Balancing Quality of Life and Glaucoma

Oct 31, 2024 | glaucomaphysician.net | Nathan M. Radcliffe

How does one treat glaucoma? Of course, the only proven therapy at this point in time is lowering intraocular pressure (IOP). My favorite answer to this question has always been that the goal of glaucoma treatment is to maintain the patient’s vision-related quality of life without decreasing the patient’s quality of life. With this goal in mind, the practical answer is to lower IOP in a way that maximizes the patient’s overall quality of life.
Regeneron Leaders Recognized for Innovation at Eyecelerator 2024

Oct 25, 2024 | glaucomaphysician.net | Jim Gallagher

“The pathway to progress is not always a straight line,” noted Allen C. Ho, MD, during an Eyecelerator 2024 program titled “The Power of Innovation and Perseverance.” During that session in Chicago, Dr. Ho and Robert L. Avery, MD, presented the inaugural Eyecelerator Innovation Award to Regeneron co-founders Leonard Schleifer, MD, PhD, and George Yancopoulos, MD, PhD.
An Update on SLT Clinical Trials

Oct 22, 2024 | glaucomaphysician.net | Jim Gallagher

The ongoing COAST trial will help to clarify the timing and energy for optimal selective laser trabeculoplasty (SLT) retreatment, Tony Realini, MD, MPH, said Sunday at the 2024 American Academy of Ophthalmology meeting in Chicago.
Spotlight: An Option for Interventional Glaucoma

Aug 31, 2024 | glaucomaphysician.net | Karen Appold

Glaukos’s iStent infinite Trabecular Micro-Bypass System is the first FDA-cleared microinvasive implantable device that can be used in combination with cataract surgery or as a standalone treatment option for glaucoma patients not undergoing concomitant cataract surgery.
KDB Glide Receives Expanded 510k Clearance

Jun 1, 2024 | glaucomaphysician.net | Jim Gallagher

The US Food and Drug Administration recently expanded its 510(k) clearance for KDB Glide (New World Medical), making it the only goniotomy device indicated for the excision of trabecular meshwork (TM) to reduce intraocular pressure (IOP) in adult patients with primary open-angle glaucoma. The KDB Glide can be used either during cataract surgery or as a stand-alone microinvasive glaucoma surgery (MIGS) procedure.
From the Editor: Shifting Toward Interventional Glaucoma

May 31, 2024 | glaucomaphysician.net | Nathan M. Radcliffe

If you look at the evolving treatment landscape in glaucoma from 30,000 feet, a few things seem obvious. The first is that selective laser trabeculoplasty (SLT) is moving into the position of primary therapy, standing on the shoulders of the prospective multicenter LiGHT trial.1 Even this relatively straightforward change will result in dramatic adaptations from ophthalmologists a well as optometrists.
Product Spotlight: The First Preservative-free Eye Drop for Glaucoma Debuts

May 31, 2024 | glaucomaphysician.net | Karen Appold

Prolonged use of eye drops with preservatives have been shown to negatively affect the ocular surface and other anatomic structures of the eye, which can cause discomfort for patients. With the FDA’s approval of Thea’s Iyuzeh, there is now a preservative-free eye latanoprost drop to treat primary open-angle glaucoma or ocular hypertension in the United States. Iyuzeh (latanoprost ophthalmic solution) 0.005% is marketed as Monoprost outside of the United States.